SPRINT — Sprint Bioscience AB Share Price
0.000.00%
Last trade - 00:00- SEK90.63m
- SEK50.74m
- SEK50.49m
- 62
- 70
- 55
- 69
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 1.72 | ||
| PEG Ratio (f) | 0.02 | ||
| EPS Growth (f) | 524.09% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.25 | ||
| Price to Tang. Book | 4.25 | ||
| Price to Free Cashflow | 8.32 | ||
| Price to Sales | 1.54 | ||
| EV to EBITDA | 7.86 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 31.28% | ||
| Return on Equity | 43.2% | ||
| Operating Margin | 11.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 33.54 | 16.89 | 35.11 | 0.08 | 50.48 | 98 | 210 | 22.99% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +400 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Directors
- Rune Nordlander NEC (62)
- Erik Kinnman CEO (63)
- Svein Mathisen NVC (65)
- Mathias Skalmstad CFO
- Jessica Martinsson COO (49)
- Martin Andersson OTH (50)
- Anne-Marie Wenthzel OTH (57)
- Erik Bjoerk IND (45)
- Fredrik Lehmann IND (44)
- Jan-Erik Nystroem IND (68)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- September 28th, 2009
- Public Since
- November 7th, 2014
- No. of Employees
- 36
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 69,820,090
- Address
- Novum, Halsovagen 7, Floor 8, elevator A, HUDDINGE, 141 57
- Web
- https://www.sprintbioscience.com/
- Phone
- +46 84114455
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Upcoming Events for SPRINT
Q3 2024 Sprint Bioscience AB Earnings Release
Similar to SPRINT
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
FAQ
What is the Sprint Bioscience AB share price?
As of Today at 23:26 UTC, shares in Sprint Bioscience AB are trading at SEK1.50. This share price information is delayed by 15 minutes.
How has the Sprint Bioscience AB share price performed this year?
Shares in Sprint Bioscience AB last closed at SEK1.50 and the price had moved by +187.02% over the past 365 days. In terms of relative price strength the Sprint Bioscience AB share price has outperformed the FTSE Global All Cap Index by +152.41% over the past year.
What are the analyst and broker recommendations for Sprint Bioscience AB?
There is no consensus recommendation for this security.
What is the Sprint Bioscience AB dividend yield?
Sprint Bioscience AB does not currently pay a dividend.
Does Sprint Bioscience AB pay a dividend?
Sprint Bioscience AB does not currently pay a dividend.
When does Sprint Bioscience AB next pay dividends?
Sprint Bioscience AB does not currently pay a dividend.
How do I buy Sprint Bioscience AB shares?
To buy shares in Sprint Bioscience AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sprint Bioscience AB?
As of the previous close price of SEK1.50, shares in Sprint Bioscience AB had a market capitalisation of SEK105.01m.
Where are Sprint Bioscience AB shares listed?
Here are the trading details for Sprint Bioscience AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: SPRINT
What kind of share is Sprint Bioscience AB?
Based on an overall assessment of its quality, value and momentum Sprint Bioscience AB is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sprint Bioscience AB share price forecast for 2024?
The analyst consensus target price for shares in Sprint Bioscience AB is SEK2.90. That is 92.82% above the last closing price of SEK1.50.
Analysts covering Sprint Bioscience AB currently have a consensus Earnings Per Share (EPS) forecast of SEK0.30 for the next financial year.
What is the trend in the Sprint Bioscience AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sprint Bioscience AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -7.13%.
As of the last closing price of SEK1.50, shares in Sprint Bioscience AB were trading +1.2% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sprint Bioscience AB PE Ratio?
The Sprint Bioscience AB PE ratio based on its reported earnings over the past 12 months is 1.72. The shares last closed at SEK1.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sprint Bioscience AB?
Sprint Bioscience AB's management team is headed by:
- Rune Nordlander - NEC
- Erik Kinnman - CEO
- Svein Mathisen - NVC
- Mathias Skalmstad - CFO
- Jessica Martinsson - COO
- Martin Andersson - OTH
- Anne-Marie Wenthzel - OTH
- Erik Bjoerk - IND
- Fredrik Lehmann - IND
- Jan-Erik Nystroem - IND